市場調查報告書
商品編碼
1388287
綜合代謝面板測試市場 - 按測試類型(葡萄糖、鈣、電解質、腎功能測試、肝功能測試、蛋白質)、按疾病適應症(腎臟疾病)Comprehensive Metabolic Panel Testing Market - By Test Type (Glucose, Calcium, Electrolytes, Kidney Function Tests, Liver Function Tests, Proteins), By Disease Indication (Kidney Diseases) |
由於慢性病盛行率不斷上升、人口老化以及對代謝紊亂早期檢測和監測的需求日益增加,綜合代謝檢測市場規模預計從 2023 年到 2032 年將以 8.7% 的複合CAGR擴大。
人們對預防保健意識的不斷增強和診斷技術的不斷進步正在推動綜合代謝組在常規健康檢查中的整合。例如,2022 年 1 月,Quest Diagnostics 透過 QuestDirect (TM) 推出了虛擬預防護理服務,使個人能夠主動管理自己的健康和福祉。對個人化醫療的需求激增以及床邊檢測的廣泛採用將進一步擴大市場成長,以滿足不同患者群體不斷變化的醫療保健需求。
綜合代謝組測試產業分為測試類型、疾病適應症、最終用途和地區。
根據測試類型,由於腎臟疾病盛行率不斷增加,預計到 2032 年,腎功能測試領域的市佔率複合CAGR將達到 8.6%。人口老化的加劇以及腎功能測試在評估和監測腎臟健康方面的關鍵作用將促進該領域的成長。
肝病適應症領域預計將在綜合代謝組測試市場中佔據相當大的佔有率,2023 年至 2032 年CAGR為 8.5%。肝臟疾病的盛行率日益增加,促使早期檢測的需求不斷增加。代謝組在評估肝功能中的關鍵作用也將推動該細分市場的擴張。
就最終用途而言,醫院細分市場的市場價值預計在 2023 年至 2032 年期間保持 8.5% 的CAGR。這是由於醫院患者數量龐大以及對快速診斷服務的需求不斷成長所推動的。此外,將代謝組常規涵蓋綜合醫療保健評估中將刺激醫院環境中的檢測需求。
從區域來看,由於代謝紊亂盛行率不斷上升以及醫療基礎設施不斷完善,亞太地區綜合代謝小組測試產業預計將在 2032 年之前以強勁速度擴張。人們對常規健康檢查的偏好不斷提高,診斷技術不斷進步,將進一步推動區域市場的成長。
Comprehensive metabolic panel testing market size is projected to expand at 8.7% CAGR from 2023 to 2032, driven by the increasing prevalence of chronic diseases, rising aging population, and the greater need for early detection and monitoring of metabolic disorders.
The growing awareness of preventive healthcare and the increasing advancements in diagnostic technologies is driving the integration of comprehensive metabolic panels in routine health check-up. For instance, in January 2022, Quest Diagnostics introduced a Virtual Preventive Care Service via QuestDirect™ for empowering individuals to proactively manage their health and well-being. The surging demand for personalized medicine and the higher adoption of point-of-care testing will further amplify the market growth to meet the evolving healthcare needs of the diverse patient population.
The comprehensive metabolic panel testing industry is segregated into test type, disease indication, end-use, and region.
Based on test type, the market share from the kidney function tests segment is projected to exhibit 8.6% CAGR through 2032, attributed to the increasing prevalence of renal disorders. The rising aging population, and the critical role of kidney function tests in assessing and monitoring kidney health will boost the segment growth.
The liver disease indication segment is projected to capture sizeable share of the comprehensive metabolic panel testing market, recording 8.5% CAGR from 2023 to2032. The increasing prevalence of liver disorders is prompting the growing need for early detection. The crucial role of metabolic panels in assessing liver function will also fuel the segment expansion.
In terms of end-use, the market value form the hospitals segment is estimated to withhold 8.5% CAGR during 2023-2032. This is driven by the high patient volume in hospitals along with the growing need for rapid diagnostic services. Moreover, the routine incorporation of metabolic panels in comprehensive healthcare assessments will fuel the testing demand in hospital settings.
Regionally, the Asia Pacific comprehensive metabolic panel testing industry is slated to expand at robust rate through 2032, led by the increasing prevalence of metabolic disorders along with growing healthcare infrastructure. The rising preference for routine health check-ups and the increasing advancements in diagnostic technologies will further boost the regional market growth.